HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off

This article was originally published in The Pink Sheet

Executive Summary

Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.

You may also be interested in...



Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues

Perrigo's third-quarter launch of private label Nexium24HR was primary contributor of $13m in new product sales in North America.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel